WeTrials
Recruiting

ShortStop-HER2: Shortened Duration of Adjuvant Therapy in Patients With Early-Stage HER2+ Breast Cancer Who Achieve pCR After Neoadjuvant Chemotherapy With HER2 Blockade

What is this study?

This study is looking at whether a shorter, 6-month course of targeted therapy works just as well as the standard 12-month course for early-stage HER2-positive breast cancer. Researchers want to see if patients who have already had a great response to treatment before surgery can safely receive fewer months of medication.

Who can participate?

This study is currently recruiting adults with early-stage HER2-positive breast cancer who had no active cancer remaining after their initial treatment before surgery. You might be able to join if you meet specific medical and tumor requirements set by the study team.

What will happen?

Each participant's group is chosen at random by chance, not by you or your doctor. One group receives 12 months of targeted therapy, while the other group receives 6 months of targeted therapy. You will also experience regular heart scans, imaging tests, and health questionnaires.

Where and when?

This study is currently recruiting participants at about 600 sites in the United States and Puerto Rico. The study team is ready to take new participants who qualify.

Key Points
  • 1Comparing a 6-month and a 12-month course of targeted therapy
  • 2Study groups are assigned by chance
  • 3Currently recruiting at about 600 locations in the United States and Puerto Rico

Related videos

2

Breast Cancers Today: study chair Dr. Waks explains the ShortStop-HER2 design (September 2025)

HER2-Positive Breast Cancer: Can Some Women Skip Chemo? What 5 Years Showed

Related links

Outside pages about this study, checked by our team

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Early Stage HER2+ Breast Cancer

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.